Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Completed · Phase 2 · Has a placebo group

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Key facts

Study ID

NCT04622345

Run by

Vanda Pharmaceuticals

People needed

47

Starts

2020-11-21

Expected to finish

2021-06-28

Last updated by the study team

2025-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age of either gender and any race
• Able to provide written informed consent and sign the HIPAA form
• Willing and able to follow all instructions and attend all study visits

You may not qualify if…

• Able and willing to avoid all disallowed medications during washout and study period

Where it is running

• Vanda Investigational Site — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.